Identity
- Security key
- 17626
- Ticker
- KALA
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2017-07-20
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- KALA
Detail
Enriched 2026-08-14 20:47
- Market cap
- $17,096,370.82
- Shares outstanding (class)
- 19,339,786
- Shares outstanding (weighted)
- 19,339,786
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 6
- Location
- ARLINGTON, MA
- Homepage
- https://www.kalarx.com
- Description
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Market cap and share counts drift.